Gain Therapeutics (GANX) Long-Term Investments (2022 - 2023)
Gain Therapeutics (GANX) posted quarterly Long-Term Investments of $988388.0 for Q1 2023, down 49.09% quarter-over-quarter from $1.9 million in Q4 2022.
Gain Therapeutics (GANX) Long-Term Investments (2022 - 2023) Analysis & Trends
Gain Therapeutics' Long-Term Investments history runs 2 years deep, the most recent figure standing at $988388.0 for Q1 2023.
- In Q1 2023, Long-Term Investments changed N/A year-over-year to $988388.0; the TTM figure through Mar 2023 stood at $988388.0 (changed N/A YoY), while the FY2022 annual figure was $1.9 million, changed N/A from the prior year.
- Long-Term Investments for Q1 2023 stood at $988388.0, down from $1.9 million in the prior quarter.
- The five-year high for Long-Term Investments was $4.9 million in Q2 2022, with the low at $988388.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 988,388.00 |
| Dec 31, 2022 | 1.94 Mn |
| Sep 30, 2022 | 2.92 Mn |
| Jun 30, 2022 | 4.92 Mn |